Cargando…
Hydralazine-Induced Isolated Lupus Nephritis
Background: Hydralazine has been known to cause multiple side effects, both localized and systemic. The literature includes case reports of systemic vasculitis caused by hydralazine. Case Report: A 79-year-old male with stage 3 chronic kidney disease attributable to hypertension and type 2 diabetes...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Division of Ochsner Clinic Foundation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310176/ https://www.ncbi.nlm.nih.gov/pubmed/32612474 http://dx.doi.org/10.31486/toj.18.0128 |
_version_ | 1783549321301458944 |
---|---|
author | Khan, Naseer Reichel, Ronald Khurshid, Ayesha Tso, Katie Broussard, Joan Dass, Amrika |
author_facet | Khan, Naseer Reichel, Ronald Khurshid, Ayesha Tso, Katie Broussard, Joan Dass, Amrika |
author_sort | Khan, Naseer |
collection | PubMed |
description | Background: Hydralazine has been known to cause multiple side effects, both localized and systemic. The literature includes case reports of systemic vasculitis caused by hydralazine. Case Report: A 79-year-old male with stage 3 chronic kidney disease attributable to hypertension and type 2 diabetes was started on hydralazine to control his hypertension. Three weeks after starting hydralazine, the patient developed nephrotic syndrome and acute kidney injury with progressively worsening proteinuria. Pathologic evaluation of the kidney tissue revealed that the patient had lupus nephritis. Immunologic markers confirmed hydralazine-induced lupus nephritis with positive antihistone antibodies. No evidence of systemic vasculitis was found. The patient's hydralazine was stopped, and the patient was treated with immunosuppressive therapy. After 7 months of immunosuppressive therapy, the patient achieved complete remission of lupus nephritis. Conclusion: Isolated renal disease induced by hydralazine as part of drug-induced lupus is uncommon. Our patient developed isolated classic lupus nephritis after hydralazine therapy with no associated systemic vasculitis. Treatment required stopping the hydralazine and initiating systemic immunosuppressive therapy to achieve complete remission. |
format | Online Article Text |
id | pubmed-7310176 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Academic Division of Ochsner Clinic Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-73101762020-06-30 Hydralazine-Induced Isolated Lupus Nephritis Khan, Naseer Reichel, Ronald Khurshid, Ayesha Tso, Katie Broussard, Joan Dass, Amrika Ochsner J Case Reports and Clinical Observations Background: Hydralazine has been known to cause multiple side effects, both localized and systemic. The literature includes case reports of systemic vasculitis caused by hydralazine. Case Report: A 79-year-old male with stage 3 chronic kidney disease attributable to hypertension and type 2 diabetes was started on hydralazine to control his hypertension. Three weeks after starting hydralazine, the patient developed nephrotic syndrome and acute kidney injury with progressively worsening proteinuria. Pathologic evaluation of the kidney tissue revealed that the patient had lupus nephritis. Immunologic markers confirmed hydralazine-induced lupus nephritis with positive antihistone antibodies. No evidence of systemic vasculitis was found. The patient's hydralazine was stopped, and the patient was treated with immunosuppressive therapy. After 7 months of immunosuppressive therapy, the patient achieved complete remission of lupus nephritis. Conclusion: Isolated renal disease induced by hydralazine as part of drug-induced lupus is uncommon. Our patient developed isolated classic lupus nephritis after hydralazine therapy with no associated systemic vasculitis. Treatment required stopping the hydralazine and initiating systemic immunosuppressive therapy to achieve complete remission. Academic Division of Ochsner Clinic Foundation 2020 2020 /pmc/articles/PMC7310176/ /pubmed/32612474 http://dx.doi.org/10.31486/toj.18.0128 Text en ©2020 by the author(s); Creative Commons Attribution License (CC BY) http://creativecommons.org/licenses/by/4.0/legalcode ©2020 by the author(s); licensee Ochsner Journal, Ochsner Clinic Foundation, New Orleans, LA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (creativecommons.org/licenses/by/4.0/legalcode) that permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Case Reports and Clinical Observations Khan, Naseer Reichel, Ronald Khurshid, Ayesha Tso, Katie Broussard, Joan Dass, Amrika Hydralazine-Induced Isolated Lupus Nephritis |
title | Hydralazine-Induced Isolated Lupus Nephritis |
title_full | Hydralazine-Induced Isolated Lupus Nephritis |
title_fullStr | Hydralazine-Induced Isolated Lupus Nephritis |
title_full_unstemmed | Hydralazine-Induced Isolated Lupus Nephritis |
title_short | Hydralazine-Induced Isolated Lupus Nephritis |
title_sort | hydralazine-induced isolated lupus nephritis |
topic | Case Reports and Clinical Observations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310176/ https://www.ncbi.nlm.nih.gov/pubmed/32612474 http://dx.doi.org/10.31486/toj.18.0128 |
work_keys_str_mv | AT khannaseer hydralazineinducedisolatedlupusnephritis AT reichelronald hydralazineinducedisolatedlupusnephritis AT khurshidayesha hydralazineinducedisolatedlupusnephritis AT tsokatie hydralazineinducedisolatedlupusnephritis AT broussardjoan hydralazineinducedisolatedlupusnephritis AT dassamrika hydralazineinducedisolatedlupusnephritis |